Genotyping, Other Clinical Variables May Predict Everolimus Treatment Effects

Share this content:

the Cancer Therapy Advisor take:

The PI3KCA gene polymorphism, lactate dehydrogenase (LDH), and histologic grade can predict the effects of everolimus treatment, while corrected calcium level and a PIK3CA gene variant may be independent prognostic factors in patients with metastatic renal cell carcinoma, a new study published online in the journal Annals of Oncology has shown.

For the prospective, single-arm, phase II trial, researchers sought to identify predictive and prognostic factors in patients with metastatic renal cell carcinoma treated with everolimus 10mg daily. Specifically, they evaluated potential biomarkers of the PI3K/AKT/mTOR pathway.

Results showed that histological grade G1/2 (HR = 2.68; 95% CI: 1.29-5.58; P = 0.0082), increased LDH before treatment (HR = 2.55; 95% CI: 1.30-4.99; P = 0.0064), and the PIK3CA gene variant rs6443624 (HR = 2.08; 95% CI: 1.11-3.89; P = 0.0254) were adverse independent predictors for everolimus treatment.

Researchers also found that elevated corrected calcium level (HR = 4.17; 95% CI: 1.66-10.51; P = 0.0024) and the PIK3CA gene variant rs6443624 (HR = 1.97; 95% CI: 1.02-3.79; P = 0.0421) may be independent prognostic factors.

The authors note that further prospective studies are warranted to confirm and validate these findings.

Bevacizumab 10mg/kg plus FOLFIRI as second-line treatment did not prolong progression-free survival
Genotyping can predict the effects of everolimus treatment in patients with metastatic renal cell carcinoma.
The aim of this study was to search for predictive and prognostic factors in patients with metastatic renal cell carcinoma (mRCC) treated with everolimus among the components of PI3K/AKT/mTOR pathway.
READ FULL ARTICLE From Annals of Oncology

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs